Lupus is an autoimmune disease characterized by inflammation of different tissues of the body. The most common type of lupus is systemic lupus erythematosus (SLE), which affects different parts of the body including internal organs. The causes of SLE are unknown but are believed to be linked to genetic, environmental, and hormonal factors. Women of childbearing ages are at greatest risk of developing SLE.
The NIAID role in lupus research includes supporting clinical trials that are conducted across the United States. The following are select studies sponsored by NIAID. The links lead to full descriptions, eligibility criteria, and contact information.
JBT-101 in Systemic Lupus Erythematosus (NCT03093402)
This clinical trial evaluates JBT-101 to resolve innate immune responses without immunosuppression in people with Lupus ages 18 to 70 years.
Randomized MMF Withdrawal in Systemic Lupus Erythematosus (NCT01946880)
This trial seeks to describe the effect of withdrawal from mycophenolate mofetil (MMF) on risk of clinically significant disease reactivation in quiescent SLE patients who have been on long-term MMF therapy.